biostudies-literatureKemp KLThe University of Queensland Graduate School Research Training Program (RTP) ScholarshipMorris Animal FoundationDestination Australia Scholarship1177-1184https://www.ebi.ac.uk/biostudies/studies/S-EPMC10937495biostudies-literatureUnknown38(2)<h4>Background</h4>Phenylbutazone is often prescribed to manage pain caused by hyperinsulinemia-associated laminitis, but in diabetic people nonsteroidal anti-inflammatory drugs increase insulin secretion and pancreatic activity.<h4>Hypothesis/objectives</h4>Investigate the effect of phenylbutazone administration on insulin secretion in horses. It was hypothesized that phenylbutazone will increase insulin secretion in horses with insulin dysregulation (ID).<h4>Animals</h4>Sixteen light breed horses, including 7 with ID.<h4>Methods</h4>Randomized cross-over study design. Horses underwent an oral glucose test (OGT) after 9 days of treatment with phenylbutazone (4.4 mg/kg IV q24h) or placebo (5 mL 0.9% saline). After a 10-day washout period, horses received the alternative treatment, and a second OGT was performed. Insulin and glucose responses were compared between groups (ID or controls) and treatments using paired t test and analyses of variance with P < .05 considered significant.<h4>Results</h4>In horses with ID, phenylbutazone treatment significantly decreased glucose concentration (P = .02), glucose area under the curve (2429 ± 501.5 vs 2847 ± 486.1 mmol/L × min, P = .02), insulin concentration (P = .03) and insulin area under the curve (17 710 ± 6676 vs 22 930 ± 8788 μIU/mL × min, P = .03) in response to an OGT. No significant effect was detected in control horses.<h4>Conclusion and clinical importance</h4>Phenylbutazone administration in horses with ID decreases glucose and insulin concentrations in response to an OGT warranting further investigation of a therapeutic potential of phenylbutazone in the management of hyperinsulinemia-associated laminitis beyond analgesia.Journal of veterinary internal medicineEffect of phenylbutazone on insulin secretion in horses with insulin dysregulation.PMC10937495D19‐EQ‐302D19-EQ-302Kemp KLSkinner JEBertin FRfalseEffect of phenylbutazone on insulin secretion in horses with insulin dysregulation.<h4>Background</h4>Phenylbutazone is often prescribed to manage pain caused by hyperinsulinemia-associated laminitis, but in diabetic people nonsteroidal anti-inflammatory drugs increase insulin secretion and pancreatic activity.<h4>Hypothesis/objectives</h4>Investigate the effect of phenylbutazone administration on insulin secretion in horses. It was hypothesized that phenylbutazone will increase insulin secretion in horses with insulin dysregulation (ID).<h4>Animals</h4>Sixteen light breed horses, including 7 with ID.<h4>Methods</h4>Randomized cross-over study design. Horses underwent an oral glucose test (OGT) after 9 days of treatment with phenylbutazone (4.4 mg/kg IV q24h) or placebo (5 mL 0.9% saline). After a 10-day washout period, horses received the alternative treatment, and a second OGT was performed. Insulin and glucose responses were compared between groups (ID or controls) and treatments using paired t test and analyses of variance with P < .05 considered significant.<h4>Results</h4>In horses with ID, phenylbutazone treatment significantly decreased glucose concentration (P = .02), glucose area under the curve (2429 ± 501.5 vs 2847 ± 486.1 mmol/L × min, P = .02), insulin concentration (P = .03) and insulin area under the curve (17 710 ± 6676 vs 22 930 ± 8788 μIU/mL × min, P = .03) in response to an OGT. No significant effect was detected in control horses.<h4>Conclusion and clinical importance</h4>Phenylbutazone administration in horses with ID decreases glucose and insulin concentrations in response to an OGT warranting further investigation of a therapeutic potential of phenylbutazone in the management of hyperinsulinemia-associated laminitis beyond analgesia.2024-01-01T00:00:00Z2024 Mar-Apr2026-06-24T03:08:32.473Z2026-06-24T03:06:03.41ZS-EPMC109374953836302910.1111/jvim.17013